{
    "clinical_study": {
        "@rank": "126257", 
        "arm_group": {
            "arm_group_label": "Naglazyme\u00ae", 
            "arm_group_type": "Experimental", 
            "description": "weekly Naglazyme\u00ae infusion for 2 years"
        }, 
        "brief_summary": {
            "textblock": "This is a single center study in which Naglazyme\u00ae will be given weekly for two years in\n      patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who\n      have previously been treated with an allogeneic transplant."
        }, 
        "brief_title": "Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome", 
        "completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Maroteaux-Lamy Syndrome", 
        "condition_browse": {
            "mesh_term": "Mucopolysaccharidosis VI"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) treated with a prior\n             allogeneic transplant >2 years previously\n\n          -  Persons currently receiving Naglazyme may be accepted into the study\n\n          -  Age > 2 years\n\n          -  >10% engrafted based on most recent testing\n\n          -  Willing to commit to traveling to the University of Minnesota every 6 months\n\n          -  Written informed consent with parent/guardian consent for children < 18 years of age\n             or persons unable to consent with minor assent if appropriate\n\n        Exclusion Criteria:\n\n          -  History of cardiac or pulmonary insufficiency or those requiring continuous\n             supplemental oxygen\n\n          -  Pregnant or breastfeeding\n\n          -  Any condition that, in the view of the investigator, places the patient at high risk\n             of poor treatment compliance or of not completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156674", 
            "org_study_id": "2014LS014", 
            "secondary_id": "MT2014-08R"
        }, 
        "intervention": {
            "arm_group_label": "Naglazyme\u00ae", 
            "description": "1 mg per kg of body weight administered once weekly as an intravenous infusion", 
            "intervention_name": "Naglazyme\u00ae", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Maroteaux-Lamy Syndrome", 
            "mucopolysaccharide VI", 
            "MPS VI"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota Medical Center, Fairview"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Administration of Intravenous Naglazyme\u00ae Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome", 
        "overall_contact": {
            "email": "braun002@umn.edu", 
            "last_name": "Elizabeth Braunlin, M.D.", 
            "phone": "612-626-2755"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Elizabeth Braulin, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change in urinary glycosaminoglycan (GAG) excretion from baseline to 2 years", 
                "measure": "Change in urinary glycosaminoglycan (GAG) excretion", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Change in distance traveled in 6 minute walk and standard tests of range of motion and mobility", 
                "measure": "Change in distance traveled", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Subjects will undergo full neuropsychological testing annually and abbreviated testing for attention and adaptive skills at the six-month interval visits", 
                "measure": "Change in neurocognitive ability", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156674"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "development of antibodies including neutralizing antibodies with weekly Naglazyme therapy and the impact of these antibodies on cardiorespiratory and skeletal parameters as measured by the 6--minute walk test and standard tests of range of motion and mobility, and the change in neurocognitive ability", 
            "measure": "development of antibodies to Naglazyme therapy", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "collaborator": {
                "agency": "BioMarin Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}